Expanding the Reach of Precision Oncology by Drugging All KRAS Mutants
KRAS is the most frequently mutated oncogene, harboring mutations in approximately one
in seven cancers. Allele-specific KRASG12C inhibitors are currently changing the treatment …
in seven cancers. Allele-specific KRASG12C inhibitors are currently changing the treatment …
Strategies targeting protein tyrosine phosphatase SHP2 for cancer therapy
Y Song, S Wang, M Zhao, X Yang… - Journal of medicinal …, 2022 - ACS Publications
The protein tyrosine phosphatase SHP2 encoded by PTPN11 is a promising therapeutic
target for cancer therapy, while the multifaceted roles of SHP2 complicate the drug discovery …
target for cancer therapy, while the multifaceted roles of SHP2 complicate the drug discovery …
[HTML][HTML] Variant rs8400 enhances ALKBH5 expression through disrupting miR-186 binding and promotes neuroblastoma progression
Q Guan, H Lin, W Hua, L Lin, J Liu, L Deng… - Chinese Journal of …, 2023 - ncbi.nlm.nih.gov
Objective AlkB homolog 5 (ALKBH5) has been proven to be closely related to tumors.
However, the role and molecular mechanism of ALKBH5 in neuroblastomas have rarely …
However, the role and molecular mechanism of ALKBH5 in neuroblastomas have rarely …
[HTML][HTML] The Q61H mutation decouples KRAS from upstream regulation and renders cancer cells resistant to SHP2 inhibitors
T Gebregiworgis, Y Kano, J St-Germain… - Nature …, 2021 - nature.com
Cancer cells bearing distinct KRAS mutations exhibit variable sensitivity to SHP2 inhibitors
(SHP2i). Here we show that cells harboring KRAS Q61H are uniquely resistant to SHP2i …
(SHP2i). Here we show that cells harboring KRAS Q61H are uniquely resistant to SHP2i …
Discovery of novel Src homology-2 domain-containing phosphatase 2 and histone deacetylase dual inhibitors with potent antitumor efficacy and enhanced antitumor …
M Liu, S Gao, T Liang, X Qiu, X Yang… - Journal of Medicinal …, 2022 - ACS Publications
Both Src homology-2 domain-containing phosphatase 2 (SHP2) and histone deacetylase
(HDAC) are important oncoproteins and potential immunomodulators. In this study, we first …
(HDAC) are important oncoproteins and potential immunomodulators. In this study, we first …
[HTML][HTML] High-risk neuroblastoma with NF1 loss of function is targetable using SHP2 inhibition
Reoccurring/high-risk neuroblastoma (NB) tumors have the enrichment of non-RAS/RAF
mutations along the mitogen-activated protein kinase (MAPK) signaling pathway, suggesting …
mutations along the mitogen-activated protein kinase (MAPK) signaling pathway, suggesting …
[HTML][HTML] A review of the biological and clinical implications of RAS-MAPK pathway alterations in neuroblastoma
V Mlakar, E Morel, SJ Mlakar, M Ansari… - Journal of Experimental …, 2021 - Springer
Neuroblastoma is the most common extra-cranial solid tumor in children, representing
approximately 8% of all malignant childhood tumors and 15% of pediatric cancer-related …
approximately 8% of all malignant childhood tumors and 15% of pediatric cancer-related …
Crystallographic landscape of SHP2 provides molecular insights for SHP2 targeted drug discovery
Y Song, X Yang, S Wang, M Zhao… - Medicinal Research …, 2022 - Wiley Online Library
The protein tyrosine phosphatase SHP2 encoded by PTPN11 is a promising therapeutic
target for cancer therapy. The dynamic change of SHP2 between closed and open …
target for cancer therapy. The dynamic change of SHP2 between closed and open …
[HTML][HTML] The role of wild-type RAS in oncogenic RAS transformation
E Sheffels, RL Kortum - Genes, 2021 - mdpi.com
The RAS family of oncogenes (HRAS, NRAS, and KRAS) are among the most frequently
mutated protein families in cancers. RAS-mutated tumors were originally thought to …
mutated protein families in cancers. RAS-mutated tumors were originally thought to …
[HTML][HTML] Pharmacological inhibition of Ref-1 enhances the therapeutic sensitivity of papillary thyroid carcinoma to vemurafenib
L Hu, J Zhang, M Tian, N Kang, G Xu, J Zhi… - Cell death & …, 2022 - nature.com
The use of the BRAF inhibitor vemurafenib exhibits drug resistance in the treatment of
thyroid cancer (TC), and finding more effective multitarget combination therapies may be an …
thyroid cancer (TC), and finding more effective multitarget combination therapies may be an …